Detalles de la búsqueda
1.
A family history of breast cancer will not predict female early onset breast cancer in a population-based setting.
BMC Cancer
; 8: 203, 2008 Jul 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-18651949
2.
Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition.
N Engl J Med
; 351(5): 427-37, 2004 Jul 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-15282350
3.
Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic.
Ann Surg Oncol
; 14(12): 3335-44, 2007 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-17541692
4.
Primary endpoint discrepancies were found in one in ten clinical drug trials. Results of an inception cohort study.
J Clin Epidemiol
; 89: 199-208, 2017 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-28535887
5.
Recruitment failure and futility were the most common reasons for discontinuation of clinical drug trials. Results of a nationwide inception cohort study in the Netherlands.
J Clin Epidemiol
; 88: 140-147, 2017 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-28487159
6.
Non-Publication Is Common among Phase 1, Single-Center, Not Prospectively Registered, or Early Terminated Clinical Drug Trials.
PLoS One
; 11(12): e0167709, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-27973571
7.
Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation.
J Clin Oncol
; 21(9): 1675-81, 2003 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-12721241
8.
Hereditary breast cancer growth rates and its impact on screening policy.
Eur J Cancer
; 41(11): 1610-7, 2005 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-15978801
9.
Occurrence and determinants of selective reporting of clinical drug trials: design of an inception cohort study.
BMJ Open
; 5(7): e007827, 2015 Jul 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-26152325
10.
Tailoring breast cancer therapy to genetic status.
Lancet
; 365(9472): 1672-3, 2005.
Artículo
en Inglés
| MEDLINE | ID: mdl-15894086
11.
[Patient safety in clinical intervention research]. / Patiëntveiligheid bij klinisch interventieonderzoek.
Ned Tijdschr Geneeskd
; 155: A2359, 2011.
Artículo
en Neerlandesa
| MEDLINE | ID: mdl-21342593
12.
Standard psychological consultations and follow up for women at increased risk of hereditary breast cancer considering prophylactic mastectomy.
Hered Cancer Clin Pract
; 7(1): 6, 2009 Mar 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-19338651
13.
Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers.
J Clin Oncol
; 27(23): 3764-71, 2009 Aug 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-19564533
14.
Distant disease-free interval, site of first relapse and post-relapse survival in BRCA1- and BRCA2-associated compared to sporadic breast cancer patients.
Breast Cancer Res Treat
; 111(2): 303-11, 2008 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-17952592
15.
Selection bias influences reported contralateral breast cancer incidence and survival in high risk non-BRCA1/2 patients.
Breast Cancer Res Treat
; 95(2): 117-23, 2006 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-16319990
16.
Differences between first and subsequent rounds of the MRISC breast cancer screening program for women with a familial or genetic predisposition.
Cancer
; 106(11): 2318-26, 2006 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-16615112
17.
Factors affecting sensitivity and specificity of screening mammography and MRI in women with an inherited risk for breast cancer.
Breast Cancer Res Treat
; 100(1): 109-19, 2006 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-16791481
18.
Outcome of surveillance and prophylactic salpingo-oophorectomy in asymptomatic women at high risk for ovarian cancer.
Gynecol Oncol
; 97(2): 476-82, 2005 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-15863147
19.
Risk factors and risk reduction of breast and ovarian cancer.
Curr Opin Obstet Gynecol
; 15(1): 63-8, 2003 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-12544504
20.
One year follow-up of women opting for presymptomatic testing for BRCA1 and BRCA2: emotional impact of the test outcome and decisions on risk management (surveillance or prophylactic surgery).
Breast Cancer Res Treat
; 73(2): 97-112, 2002 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-12088120